Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report
© Masui et al.; licensee BioMed Central Ltd. 2013
Received: 22 December 2012
Accepted: 4 August 2013
Published: 14 August 2013
Pancreatic cancer patients with para-aortic lymph node metastasis have a poor prognosis and patients living longer than 3 years are rare. We had a patient with pancreatic cancer who survived for more than 10 years after removal of the para-aortic lymph node metastasis. A 57-year-old woman was diagnosed with pancreatic head cancer and underwent a pancreaticoduodenectomy with subtotal gastric resection following Whipple reconstruction in 2000. Para-aortic lymph node metastasis was detected during the operation by intraoperative pathological diagnosis and an extended lymphadenectomy was performed with vascular skeletonization of the celiac and superior mesenteric arteries. In 2004, a low-density area was detected around the superior mesenteric artery (SMA) 5 cm from its root and she was treated with gemcitabine, and the area was undetectable after 3 years of treatment. In 2010, computed tomography showed a low-density area around the same lesion with an increased carcinoembryonic antigen level. After 4 months of gemcitabine treatment, we resected the tumor en bloc with the associated superior mesenteric vein and perineural tissue. Histopathological examination of the resected specimen revealed a well-differentiated tubular adenocarcinoma that closely resembled the original primary pancreatic cancer, indicating perineural recurrence 10 years after the initial resection. She had no recurrence around the SMA for more than one year. Although a meta-analysis has not proved the efficacy of preventive radical dissection, this case indicates that a patient with well-differentiated, chemotherapy-responsive pancreatic cancer with para-aortic lymph node metastasis could have a long survival time through extended dissection of the lymph nodes.
KeywordsPancreatic cancer Para-aortic lymph node metastasis
Median survival time of patients affected by pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis
Number of patients
Percentage with PALN metastasis
Three-year survival with PALN metastasis
Median survival time (months) with PALN metastasis
Murakami et al. 
Doi et al. 
Shimada et al. 
Sakai et al. 
Yoshida et al. 
Kayahara et al. 
No specific abdominal tumor was palpable by physical examination. No superficial lymph nodes were palpable. There was only a slight tenderness on the upper abdomen. Laboratory findings indicated slightly high levels of total bilirubin and amylase. The levels of sialyl Lewis A (CA19-9) and carcinoembryonic antigen (CEA) were normal. In December 2000, we performed a pancreaticoduodenectomy and a subtotal gastric resection. No ascites or peritoneal neoplastic dissemination were found. The tumor was palpable at the pancreatic head. There was no serosal invasion, but a retroperitoneal invasion was observed. We performed an extended lymphadenectomy and exeresis of the para-caval and para-aortic lymph nodes, because of the intraoperative pathological diagnosis of metastasis to the para-aortic lymph nodes (Figure 1c). We also performed a neural dissection around the root of the SMA.
The size of the tumor was 2.8 × 2.0 × 2.0 cm. Histopathological analysis revealed the tumor to be a well-differentiated tubular adenocarcinoma (Figure 1b). The tumor and the lymph node metastasis stained positive for cytokeratin AE3/AE4, which implies an epithelial origin (data not shown). The tumor histologically showed vascular, lymphatic and neural invasion and no cancerous region was found at around the resection edge. Metastasis was observed in lymph nodes 12b, 16b1 and 16a2 (2/3, 2/2 and 3/4 respectively) (Figure 1c). The final International Union Against Cancer tumor-node-metastasis classification was T3N1M1 (LYM) stage 4.
In patients with adenocarcinoma of the head of the pancreas, one of the factors predicting long-term survival is the absence of metastatic lymph nodes [13, 14]. Therefore, to increase survival, extended lymphadenectomies have been performed since the 1990s. However, this extended procedure was not found to be beneficial for overall survival and seemed to be associated with increased morbidity compared with the standard procedure .
Para-aortic lymph node metastasis has been observed in around 14% to 26% of patients who underwent pancreaticoduodenectomy [7–12]. Thus far, there have been six retrospective surveys on the survival of patients with pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis, and no patient survived longer than 5 years (Table 1). However, our patient survived for more than 10 years, although the tumor recurred in the perineural tissue of the SMA. Several factors for long survival times for pancreatic cancer patients have been reported, including a low pre CA19-9 level, the negativity of the dissected margin of the tumor , tumor differentiation [2, 6, 17] and the number of lymph node metastases . Massucco et al. claimed that not only the number but also the localization of the metastases determines the prognosis . In our case, we assume that the long survival time is due to the characteristics of the tumor and the extent of the operation: (1) the original tumor was a well-differentiated adenocarcinoma, (2) it showed good response to chemotherapy and (3) an extended lymphadenectomy was performed, which achived a negative margin status.
Egawa et al. reported to the National Pancreatic Cancer Registry that patients living longer than 5 years after curative resection are those who have well-differentiated primitive tumors, such as a papillary carcinoma or a well-differentiated adenocarcinoma, with good chemosensitivity [2, 17]. Our patient had a well-differentiated carcinoma and was treated with gemcitabine for 3 years. The perineural recurrence around the SMA almost completely vanished with this treatment. The long survival time is apparently due to the good response of the tumor to the gemcitabine treatment. However, after a 2-year interval, the tumor recurred again and showed no progression or regression on further treatment with gemcitabine. Therefore, surgical resection was deemed necessary. Recently Marechal et al. reported that high activities of gemcitabine transport and metabolism proteins are important for long survival times after gemcitabine adjuvant therapy , suggesting that a tumor that responds well to gemcitabine treatment is genetically different from a non-responder. Genetic alterations that affect a tumor’s response to gemcitabine treatment should be analyzed when selecting patients for extended lymphadenectomy.
Also, the extended lymphadenectomy seemed to be important for our patient. Indeed, we did not find any recurrent tumor around the aorta but in the perineural tissue around the SMA. Although randomized trials have concluded that the addition of extended lymphadenectomy and retroperitoneal soft tissue clearance does not significantly improve overall survival , surgical resection has provided the only chance for long-term survival in pancreatic cancer patients, and exeresis of the metastatic lymph node may be worthwhile for patients with chemotherapy-responsive and well-differentiated pancreatic cancer defined by ultrasound-guided fine needle aspiration cytology.
Recently, Kato et al. reported that initially unresectable pancreatic cancer patients with a long-term favorable response to chemotherapy have long survival times after adjuvant surgery . They found 50% of these patients survived for more than 5 years. Interestingly, their analysis showed that distant metastasis, such as peritoneal dissemination and liver metastasis rather than local invasion, results in poor prognosis. But they found only one case of metastasis in the para-aortic lymph nodes. In our case, the tumor recurring around the SMA had a good response to gemcitabine and was successfully resected with at least 1 year of disease-free survival. Therefore, neoadjuvant chemotherapy or adjuvant surgery could be an effective choice for patients with local recurrence even for pancreatic cancer.
In conclusion, we observed a case of pancreatic cancer complicated by a para-aortic lymph node metastasis. After an extended lymphadenectomy, the patient survived for more than 10 years. According to our experience, for a local tumoral recurrence treated by chemotherapy, a further improvement in survival can be achieved by carefully selecting patients to undergo adjuvant surgical treatment.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
Median survival time
Superior mesenteric artery
Superior mesenteric vein.
- Cress RD, Yin D, Clarke L, Bold R, Holly EA: Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control. 2006, 17: 403-409. 10.1007/s10552-005-0539-4.View ArticlePubMedGoogle Scholar
- Egawa S, Sunamura M, Abe H, Motoi F, Fukuyama S, Matsuno S: Clinicopathological aspects of pancreatic cancer. Gan To Kagaku Ryoho (Jpn J Cancer Chemother). 2005, 32: 605-611. (in Japanese)Google Scholar
- Livingston EH, Welton ML, Reber HA: Surgical treatment of pancreatic cancer. The United States experience. Int J Pancreatol. 1991, 9: 153-157.PubMedGoogle Scholar
- Niederhuber JE, Brennan MF, Menck HR: The National Cancer Data Base report on pancreatic cancer. Cancer. 1995, 76: 1671-1677. 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R.View ArticlePubMedGoogle Scholar
- Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann Surg. 1995, 221: 59-66. 10.1097/00000658-199501000-00007.PubMed CentralView ArticlePubMedGoogle Scholar
- Yamamoto M, Ohashi O, Saitoh Y: Japan Pancreatic Cancer Registry: current status. Pancreas. 1998, 16: 238-242. 10.1097/00006676-199804000-00006.View ArticlePubMedGoogle Scholar
- Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T: Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg. 2010, 34: 1900-1907. 10.1007/s00268-010-0577-2.View ArticlePubMedGoogle Scholar
- Doi R, Kami K, Ito D, Fujimoto K, Kawaguchi Y, Wada M, Kogire M, Hosotani R, Imamura M, Uemoto S: Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg. 2007, 31: 147-154. 10.1007/s00268-005-0730-5.View ArticlePubMedGoogle Scholar
- Shimada K, Sakamoto Y, Sano T, Kosuge T: The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg. 2006, 203: 345-352. 10.1016/j.jamcollsurg.2006.05.289.View ArticlePubMedGoogle Scholar
- Sakai M, Nakao A, Kaneko T, Takeda S, Inoue S, Kodera Y, Nomoto S, Kanazumi N, Sugimoto H: Para-aortic lymph node metastasis in carcinoma of the head of the pancreas. Surgery. 2005, 137: 606-611. 10.1016/j.surg.2005.02.009.View ArticlePubMedGoogle Scholar
- Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S: Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg. 2004, 187: 736-740. 10.1016/j.amjsurg.2003.07.031.View ArticlePubMedGoogle Scholar
- Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Ueno K, Tajima H, Elnemr A, Miwa K: Analysis of paraaortic lymph node involvement in pancreatic carcinoma: a significant indication for surgery?. Cancer. 1999, 85: 583-590. 10.1002/(SICI)1097-0142(19990201)85:3<583::AID-CNCR8>3.0.CO;2-J.View ArticlePubMedGoogle Scholar
- House MG, Gonen M, Jarnagin WR, D’Angelica M, DeMatteo RP, Fong Y, Brennan MF, Allen PJ: Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007, 11: 1549-1555. 10.1007/s11605-007-0243-7.View ArticlePubMedGoogle Scholar
- Schwarz RE, Smith DD: Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol. 2006, 13: 1189-1200. 10.1245/s10434-006-9016-x.View ArticlePubMedGoogle Scholar
- Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW, Friess H: Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg. 2007, 94: 265-273. 10.1002/bjs.5716.View ArticlePubMedGoogle Scholar
- Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009, 16: 1231-1240. 10.1245/s10434-009-0415-7.View ArticlePubMedGoogle Scholar
- Hatori T, Yoshikawa T, Nakasato T, Harada N, Takasaki K: Strategy of surgical management for invasive ductal adenocarcinoma of the pancreas by clinical analysis of the long-term survivors. Nihon Shokaki Gekagakkaishi (Jpn J Gastroenterology). 1999, 32: 1089-1093. 10.5833/jjgs.32.1089.View ArticleGoogle Scholar
- Massucco P, Ribero D, Sgotto E, Mellano A, Muratore A, Capussotti L: Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers. Ann Surg Oncol. 2009, 16: 3323-3332. 10.1245/s10434-009-0672-5.View ArticlePubMedGoogle Scholar
- Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andre T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF, Van Laethem JL: Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 2012, 143: e6-e674. 10.1053/j.gastro.2012.04.013.View ArticleGoogle Scholar
- Kato K, Kondo S, Hirano S, Tanaka E, Shichinohe T, Tsuchikawa T, Matsumoto J: Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy. J Hepatobiliary Pancreat Sci. 2011, 18: 712-716. 10.1007/s00534-011-0391-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.